What is the current valuation of the US encephalomyelitis market in 2024?

The overall market valuation was $409.5 Million in 2024. Read More

What is the projected market valuation for the US encephalomyelitis market by 2035?

The projected valuation for 2035 is $805.1 Million. Read More

What is the expected CAGR for the US encephalomyelitis market during the forecast period 2025 - 2035?

The expected CAGR during the forecast period 2025 - 2035 is 6.34%. Read More

Which companies are the key players in the US encephalomyelitis market?

Key players include Novartis, Roche, Sanofi, Bristol-Myers Squibb, Merck & Co., Pfizer, AstraZeneca, Gilead Sciences, and Teva Pharmaceutical Industries. Read More

What are the main segments of the US encephalomyelitis market?

The main segments include Type, Diagnosis Method, Treatment Type, and End User. Read More

What was the market size for Acute Encephalomyelitis in 2024?

The market size for Acute Encephalomyelitis was $100.0 Million in 2024. Read More

How much is the market for Serological Testing projected to grow by 2035?

The market for Serological Testing is projected to grow from $159.5 Million in 2024 to a higher valuation by 2035. Read More

What is the expected market size for Corticosteroids in 2024?

The expected market size for Corticosteroids was $120.0 Million in 2024. Read More

Which end user segment had the highest valuation in 2024?

The Hospitals segment had the highest valuation at $150.0 Million in 2024. Read More

What is the projected growth for the Viral Encephalomyelitis segment by 2035?

The Viral Encephalomyelitis segment is projected to grow from $139.5 Million in 2024 to a higher valuation by 2035. Read More

US Encephalomyelitis Market

US Encephalomyelitis Market Research Report By Type (Acute Encephalomyelitis, Post-Infectious Encephalomyelitis, Autoimmune Encephalomyelitis, Viral Encephalomyelitis), By Diagnosis Method (MRI Scan, CT Scan, Lumbar Puncture, Serological Testing), By Treatment Type (Antiviral Medication, Immunotherapy, Corticosteroids, Supportive Care) and By End User (Hospitals, Clinics, Research Institutions) - Growth & Industry Forecast 2025 To 2035

Forecast Period

2025 - 2035

CAGR

6.34%

2024 Market Size

$ 409.5 Million

2035 Market Size

$ 805.1 Million

Pharmaceutical ● Updated August 2026 Report ID: MRFR/Pharma/18382-HCR | Pages: 100 | Author: Satyendra Maurya, Garvit Vyas

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Food, Beverages & Nutrition, BY Type (USD Million)
  1. 4.1.1 Acute Encephalomyelitis
  2. 4.1.2 Post-Infectious Encephalomyelitis
  3. 4.1.3 Autoimmune Encephalomyelitis
  4. 4.1.4 Viral Encephalomyelitis
2. 4.2 Food, Beverages & Nutrition, BY Diagnosis Method (USD Million)
  1. 4.2.1 MRI Scan
  2. 4.2.2 CT Scan
  3. 4.2.3 Lumbar Puncture
  4. 4.2.4 Serological Testing
3. 4.3 Food, Beverages & Nutrition, BY Treatment Type (USD Million)
  1. 4.3.1 Antiviral Medication
  2. 4.3.2 Immunotherapy
  3. 4.3.3 Corticosteroids
  4. 4.3.4 Supportive Care
4. 4.4 Food, Beverages & Nutrition, BY End User (USD Million)
  1. 4.4.1 Hospitals
  2. 4.4.2 Clinics
  3. 4.4.3 Research Institutions
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Food, Beverages & Nutrition
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Food, Beverages & Nutrition
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Novartis (CH)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Roche (CH)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Sanofi (FR)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Bristol-Myers Squibb (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Merck & Co. (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Pfizer (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 AstraZeneca (GB)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Gilead Sciences (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Teva Pharmaceutical Industries (IL)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY TYPE
3. 6.3 US MARKET ANALYSIS BY DIAGNOSIS METHOD
4. 6.4 US MARKET ANALYSIS BY TREATMENT TYPE
5. 6.5 US MARKET ANALYSIS BY END USER
6. 6.6 KEY BUYING CRITERIA OF FOOD, BEVERAGES & NUTRITION
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF FOOD, BEVERAGES & NUTRITION
9. 6.9 DRIVERS IMPACT ANALYSIS: FOOD, BEVERAGES & NUTRITION
10. 6.10 RESTRAINTS IMPACT ANALYSIS: FOOD, BEVERAGES & NUTRITION
11. 6.11 SUPPLY / VALUE CHAIN: FOOD, BEVERAGES & NUTRITION
12. 6.12 FOOD, BEVERAGES & NUTRITION, BY TYPE, 2024 (% SHARE)
13. 6.13 FOOD, BEVERAGES & NUTRITION, BY TYPE, 2024 TO 2035 (USD Million)
14. 6.14 FOOD, BEVERAGES & NUTRITION, BY DIAGNOSIS METHOD, 2024 (% SHARE)
15. 6.15 FOOD, BEVERAGES & NUTRITION, BY DIAGNOSIS METHOD, 2024 TO 2035 (USD Million)
16. 6.16 FOOD, BEVERAGES & NUTRITION, BY TREATMENT TYPE, 2024 (% SHARE)
17. 6.17 FOOD, BEVERAGES & NUTRITION, BY TREATMENT TYPE, 2024 TO 2035 (USD Million)
18. 6.18 FOOD, BEVERAGES & NUTRITION, BY END USER, 2024 (% SHARE)
19. 6.19 FOOD, BEVERAGES & NUTRITION, BY END USER, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Million)
  3. 7.2.3 BY TREATMENT TYPE, 2025-2035 (USD Million)
  4. 7.2.4 BY END USER, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Encephalomyelitis Market Segmentation

US Encephalomyelitis Market By Type (USD Million, 2025-2035)

Acute Encephalomyelitis
Post-Infectious Encephalomyelitis
Autoimmune Encephalomyelitis
Viral Encephalomyelitis

US Encephalomyelitis Market By Diagnosis Method (USD Million, 2025-2035)

MRI Scan
CT Scan
Lumbar Puncture
Serological Testing

US Encephalomyelitis Market By Treatment Type (USD Million, 2025-2035)

Antiviral Medication
Immunotherapy
Corticosteroids
Supportive Care

US Encephalomyelitis Market By End User (USD Million, 2025-2035)

Hospitals
Clinics
Research Institutions

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”